Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
Aeglea BioTherapeutics (NASDAQ: AGLE) announced that the FDA has granted Orphan Drug Designation for ACN00177 to treat Homocystinuria, a serious metabolic disorder. The European Medicines Agency also recommended Orphan Drug Designation for the same treatment. ACN00177 aims to reduce elevated homocysteine levels, which can cause severe complications. The FDA designation offers benefits like market exclusivity and tax credits. Aeglea plans to initiate its Phase 1/2 clinical trial, aiming to provide impactful therapy for patients suffering from this condition.
- FDA granted Orphan Drug Designation for ACN00177, indicating regulatory support.
- Positive opinion from EMA for Orphan Drug Designation, enhancing market potential.
- ACN00177 designed to treat unmet medical need in Homocystinuria, potentially improving patient outcomes.
- None.
AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine which leads to a wide range of life-altering complications and reduced life expectancy. Additionally, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug Designation for ACN00177 for the treatment of Homocystinuria in the European Union. ACN00177 is a novel engineered human enzyme therapy designed to lower the total level of homocysteine in the plasma.
"People with Homocystinuria are living with serious complications, including severe vision issues, skeletal abnormalities, intellectual disability and a high risk of thrombosis which is a common cause of early death, yet many patients do not have effective treatments. These designations underscore the very high unmet need for new treatments for this progressive disease and reaffirms our belief that ACN00177 has the potential to change the lives of people with Homocystinuria," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "We look forward to dosing the first person in our Phase 1/2 clinical trial of ACN00177 which will move us one step closer to our goal of providing an impactful therapy for people with Homocystinuria who are in need of new treatment options."
The FDA grants Orphan Drug Designation to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The designation provides certain benefits, including the potential for up to seven years of market exclusivity upon FDA approval, prescription drug user fee waivers and tax credits for qualified clinical trials. The EMA's Orphan Drug Designation provides benefits, such as protocol assistance, fee reductions and up to ten years of market exclusivity upon regulatory approval, to companies working to develop treatments for life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the EU and where no satisfactory treatments are available.
About ACN00177 in Homocystinuria
Aeglea is developing ACN00177 for the treatment of patients with cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria. Homocysteine accumulation plays a key role in multiple progressive and serious disease-related complications, including thromboembolic vascular events, skeletal abnormalities including severe osteoporosis, developmental delay, intellectual disability, lens dislocation and severe near-sightedness. ACN00177 has been designed as a novel recombinant human enzyme, which degrades the amino acid homocysteine and its related homocystine dimer. With this mechanism, ACN00177 is intended to lower the abnormally high blood levels of homocysteine in patients with Homocystinuria. Preclinical data demonstrated that ACN00177 improved important disease-related abnormalities and survival in a mouse model of Homocystinuria. The Company initiated a Phase 1/2 trial in the second quarter of 2020 and continues patient identification and administrative activities.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, the potential addressable markets of the our product candidates and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-us-and-eu-orphan-drug-designations-for-acn00177-for-the-treatment-of-homocystinuria-301159052.html
SOURCE Aeglea BioTherapeutics, Inc.
FAQ
What drug received Orphan Drug Designation from the FDA for Homocystinuria treatment?
What is the significance of Orphan Drug Designation for ACN00177?
When will Aeglea begin clinical trials for ACN00177?
What are the complications of Homocystinuria?
How does ACN00177 function in treating Homocystinuria?
